drugset / Trial / NCT01746004

A Study of LY2157299 Monohydrate in Healthy Volunteers

NCT01746004

Phase 1 Completed 8 enrolled Eli Lilly and Company
NaSingle-groupOpen-labelBasic science

Summary

This study involves a single dose of 150 milligram (mg) of radiolabeled LY2157299 monohydrate in healthy participants. The study will determine how the body eliminates the radioactivity and LY2157299 monohydrate. Participants must be healthy surgically sterile or postmenopausal females, or sterile males. This study is approximately 8 to 15 days.

Timeline

Start
2013-01
Primary completion
2013-02
Completion
2013-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Galunisertib Small molecule 150 mg Oral

Indications

No indication recorded.